

Evoform Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi

-- Evoform now has four Orange Book listed patents covering Phexxi into 2033 --

SAN DIEGO, Feb. 27, 2023 /[PRNewswire](#)/ -- Evoform Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover [Phexxi®](#) (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication *Approved Drug Products with Therapeutic Equivalence Evaluations*, commonly known as the *Orange Book*.

"The *Orange Book* listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evoform Biosciences CEO Sandra Pelletier. "We plan to further expand our intellectual property estate in the U.S. and overseas as we continue to iterate our vaginal pH modulator platform and seek entry into global markets."

The newly listed U.S. Patent No. 11,337,989 (the '989 patent) covers contraception using the L-Lactic Acid Phexxi formulation. The '989 patent was issued by the U.S. Patent and Trademark Office (USPTO) on May 24, 2022 and is expected to expire in March 2033.

The newly listed U.S. Patent No. 11,439,610 (the '610 patent) covers compositions containing L-Lactic Acid, including the Phexxi formulation. The '610 patent was issued by the USPTO on September 13, 2022 and is expected to expire in March 2033.

About Evoform

Evoform Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at [phexxi.com](#) and [evoform.com](#).

Phexxi® is a registered trademark of Evoform Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements related to the expected duration of the issued patents and Evoform's plans to further expand its intellectual property estate, to iterate its vaginal pH modulator platform, and to enter into global markets. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 10, 2022, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the SEC on January 6, 2023 and any subsequent filings. All forward-looking

statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contact

Amy Raskopf

SVP, Investor Relations

Evofem Biosciences, Inc.

araskopf@evofem.com / media@evofem.com

(917) 673-5775

SOURCE Evofem Biosciences, Inc.
